ArticleJCO precision oncology2022

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.

Diana Treis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.